Skip to main content
Erschienen in: Clinical Rheumatology 9/2021

24.06.2021 | Perspectives in Rheumatology

Refractory fibromyalgia

verfasst von: Luis F. Vidal, Osvaldo Messina, Tamara Rodríguez, Maritza Vidal, Carlos Pineda, Rasec Morales, Antonio Collado

Erschienen in: Clinical Rheumatology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

In the medical literature, there are only a few references on refractory fibromyalgia and there is no consensus definition available on this concept. Some definitions of refractory fibromyalgia have been proposed based on the lack of response to a number of medications, and perhaps the most appropriate term is treatment-refractory fibromyalgia. To achieve the definition of treatment-refractory fibromyalgia, it is necessary to consider several previous steps, such as making sure the diagnosis has been made properly and a differential diagnosis with entities that can mimic fibromyalgia symptoms (including complete physical examination and laboratory test) has been made. The possibility that another factor that alters the response to treatment should be investigated, and in particular review all prescribed medication and search for some non-medical reasons that could mask the response to treatment (e.g., legal compensation). The definition of refractory fibromyalgia is complex and probably should include a lack of response to a specified number of drugs or to combination therapy with at least two non-pharmacological measures. In this article, it is not our purpose to present a formal definition, but to raise the possible bases for this purpose. We believe that it is a subject that must be discussed extensively before reaching a consensus definition.
Key Points
• There is no appropriate definition to classify fibromyalgia patients who do not respond to the usual pharmacological and non-pharmacological measures according to the national or international guidelines.
• A consensus definition is required to classify these patients, which could help standardize future management strategies. In this article, we propose the bases on which refractory fibromyalgia could be defined.
Literatur
1.
Zurück zum Zitat Häuser W, Fitzcharles MA (2018) Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci 20(1):53CrossRef Häuser W, Fitzcharles MA (2018) Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci 20(1):53CrossRef
2.
Zurück zum Zitat Arnold LM, Gebke KB, Choy EHS (2016) Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 70(2):99–112CrossRef Arnold LM, Gebke KB, Choy EHS (2016) Fibromyalgia: management strategies for primary care providers. Int J Clin Pract 70(2):99–112CrossRef
3.
Zurück zum Zitat Heymann RE, Paiva ES, Martinez JE et al (2017) New guidelines for the diagnosis of fibromyalgia. Rev Bras Reumatol 57:s467-476CrossRef Heymann RE, Paiva ES, Martinez JE et al (2017) New guidelines for the diagnosis of fibromyalgia. Rev Bras Reumatol 57:s467-476CrossRef
4.
Zurück zum Zitat Ablin JN, Buskila D (2015) Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol 29(1):20–28CrossRef Ablin JN, Buskila D (2015) Update on the genetics of the fibromyalgia syndrome. Best Pract Res Clin Rheumatol 29(1):20–28CrossRef
5.
Zurück zum Zitat Bennett R (2016) Shining a light on fibromyalgia treatment. Nat Rev Rheumatol 12(10):568–569CrossRef Bennett R (2016) Shining a light on fibromyalgia treatment. Nat Rev Rheumatol 12(10):568–569CrossRef
6.
Zurück zum Zitat Copay AG, Subach R, Glassman SD et al (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546CrossRef Copay AG, Subach R, Glassman SD et al (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546CrossRef
7.
Zurück zum Zitat Choy EH, Arnold LM, Clauw DJ et al (2009) Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 36:2330–2334CrossRef Choy EH, Arnold LM, Clauw DJ et al (2009) Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 36:2330–2334CrossRef
8.
Zurück zum Zitat Revicki D, Hays RD, Cella D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109CrossRef Revicki D, Hays RD, Cella D et al (2008) Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61(2):102–109CrossRef
9.
Zurück zum Zitat Bennet RM, Bushmakin AG, Cappelleri JC et al (2009) Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 36:1304–1311CrossRef Bennet RM, Bushmakin AG, Cappelleri JC et al (2009) Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 36:1304–1311CrossRef
10.
Zurück zum Zitat Geisser ME, Clauw DJ, Strand V et al (2010) Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 149:373–378CrossRef Geisser ME, Clauw DJ, Strand V et al (2010) Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 149:373–378CrossRef
11.
Zurück zum Zitat Arnold LM, Zlateva G, Sadosky A et al (2011) Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 12:260–267CrossRef Arnold LM, Zlateva G, Sadosky A et al (2011) Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo-controlled trials of pregabalin. Pain Med 12:260–267CrossRef
12.
Zurück zum Zitat Hudson JI, Arnold LM, Bradley LA et al (2009) What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four, randomized, placebo-controlled trials of duloxetine. J Rheumatol 36:2517–2522CrossRef Hudson JI, Arnold LM, Bradley LA et al (2009) What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four, randomized, placebo-controlled trials of duloxetine. J Rheumatol 36:2517–2522CrossRef
13.
Zurück zum Zitat Arnold LM, Williams DA, Hudson JI et al (2012) Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 64(3):885–894CrossRef Arnold LM, Williams DA, Hudson JI et al (2012) Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 64(3):885–894CrossRef
14.
Zurück zum Zitat Nuesch E, Häuser W, Bernardy K et al (2013) Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962CrossRef Nuesch E, Häuser W, Bernardy K et al (2013) Comparative efficacy of pharmacological and nonpharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis 72:955–962CrossRef
15.
Zurück zum Zitat Holman A (1998) Effect of lorazepam on pain score for refractory fibromyalgia. Arthritis Rheum 41(9) Holman A (1998) Effect of lorazepam on pain score for refractory fibromyalgia. Arthritis Rheum 41(9)
16.
Zurück zum Zitat Dworkin R, Sharma U, Stacey B et al (2005) Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. J Pain 6(3):S30CrossRef Dworkin R, Sharma U, Stacey B et al (2005) Long-term treatment of neuropathic pain and fibromyalgia syndrome with pregabalin in treatment-refractory patients. J Pain 6(3):S30CrossRef
17.
Zurück zum Zitat Stacey BR, Emir B, Petersel D et al (2010) Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J 4:35CrossRef Stacey BR, Emir B, Petersel D et al (2010) Pregabalin in treatment-refractory fibromyalgia. Open Rheumatol J 4:35CrossRef
18.
Zurück zum Zitat Fitzcharles MA, Ste-Marie PA, Goldenberg DL et al (2013) Canadian guidelines for the diagnosis and management of Fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119–126CrossRef Fitzcharles MA, Ste-Marie PA, Goldenberg DL et al (2013) Canadian guidelines for the diagnosis and management of Fibromyalgia syndrome: executive summary. Pain Res Manag 18(3):119–126CrossRef
19.
Zurück zum Zitat Fitzcharles MA, Shir Y, Ablin JN el at (2013) Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid Based Complement Alternat Med 2013:485272 Fitzcharles MA, Shir Y, Ablin JN el at (2013) Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines. Evid Based Complement Alternat Med 2013:485272
20.
Zurück zum Zitat Salaffi F, Gerardi MC, Atzeni F et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37(12):2035–2042CrossRef Salaffi F, Gerardi MC, Atzeni F et al (2017) The influence of fibromyalgia on achieving remission in patients with long-standing rheumatoid arthritis. Rheumatol Int 37(12):2035–2042CrossRef
21.
Zurück zum Zitat Fitzcharles MA, Perrot S, Häuser W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22(9):1565–1576CrossRef Fitzcharles MA, Perrot S, Häuser W (2018) Comorbid fibromyalgia: a qualitative review of prevalence and importance. Eur J Pain 22(9):1565–1576CrossRef
22.
Zurück zum Zitat Häuser W, Perrot S, Sommer C et al (2017) Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2(3) Häuser W, Perrot S, Sommer C et al (2017) Diagnostic confounders of chronic widespread pain: not always fibromyalgia. Pain Rep 2(3)
23.
Zurück zum Zitat López-Medina C, Moltó A (2020) Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis 12:1759720X20966123CrossRef López-Medina C, Moltó A (2020) Comorbid pain in axial spondyloarthritis, including fibromyalgia. Ther Adv Musculoskelet Dis 12:1759720X20966123CrossRef
24.
Zurück zum Zitat Arendt-Nielsen L, Nie H, Laursen MB et al (2010) Sensitization in patients with painful knee osteoarthritis. Pain 149(3):573–581CrossRef Arendt-Nielsen L, Nie H, Laursen MB et al (2010) Sensitization in patients with painful knee osteoarthritis. Pain 149(3):573–581CrossRef
25.
Zurück zum Zitat Fingleton C, Smart K, Moloney N et al (2015) Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 23:1043–1056CrossRef Fingleton C, Smart K, Moloney N et al (2015) Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis. Osteoarthr Cartil 23:1043–1056CrossRef
26.
Zurück zum Zitat Bazzichi L, Rossi A, Giuliano T et al (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120CrossRef Bazzichi L, Rossi A, Giuliano T et al (2007) Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 26(12):2115–2120CrossRef
27.
Zurück zum Zitat Haliloglu S, Ekinci B, Uzkeser H et al (2017) Fibromyalgia in patients with thyroid autoimmunity: prevalence and relationship with disease activity. Clin Rheumatol 36(7):1617–1621CrossRef Haliloglu S, Ekinci B, Uzkeser H et al (2017) Fibromyalgia in patients with thyroid autoimmunity: prevalence and relationship with disease activity. Clin Rheumatol 36(7):1617–1621CrossRef
28.
Zurück zum Zitat Tagoe CE, Sheth T, Golub E et al (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review. Clin Rheumatol 38(7):1801–1809CrossRef Tagoe CE, Sheth T, Golub E et al (2019) Rheumatic associations of autoimmune thyroid disease: a systematic review. Clin Rheumatol 38(7):1801–1809CrossRef
30.
Zurück zum Zitat Vidal LF, Morales R, Cueva C et al (2019) Serum levels of vitamin D in women treated at rheumatology services in Lima. Int J Clin Rheumatol 14(3):105–112 Vidal LF, Morales R, Cueva C et al (2019) Serum levels of vitamin D in women treated at rheumatology services in Lima. Int J Clin Rheumatol 14(3):105–112
31.
Zurück zum Zitat Häuser W, Perrot S, Clauw DJ et al (2018) Unravelling fibromyalgia—steps toward individualized management. J Pain 19(2):125–134CrossRef Häuser W, Perrot S, Clauw DJ et al (2018) Unravelling fibromyalgia—steps toward individualized management. J Pain 19(2):125–134CrossRef
32.
Zurück zum Zitat Affaitati G, Costantini R, Fabrizio A et al (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69CrossRef Affaitati G, Costantini R, Fabrizio A et al (2011) Effects of treatment of peripheral pain generators in fibromyalgia patients. Eur J Pain 15(1):61–69CrossRef
33.
Zurück zum Zitat Häuser W, Ablin J, Perrot S et al (2017) Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 127(1):47–56CrossRef Häuser W, Ablin J, Perrot S et al (2017) Management of fibromyalgia: practical guides from recent evidence-based guidelines. Pol Arch Intern Med 127(1):47–56CrossRef
34.
Zurück zum Zitat Smith JD, Terpening CM, Schmidt SO et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35(6):702–706CrossRef Smith JD, Terpening CM, Schmidt SO et al (2001) Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 35(6):702–706CrossRef
35.
Zurück zum Zitat Dodd S, Horgan D, Malhi GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89(1–3):1–11CrossRef Dodd S, Horgan D, Malhi GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. J Affect Disord 89(1–3):1–11CrossRef
36.
Zurück zum Zitat Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659CrossRef Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8):649–659CrossRef
37.
Zurück zum Zitat Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(16) Souery D, Papakostas GI, Trivedi MH (2006) Treatment-resistant depression. J Clin Psychiatry 67(16)
Metadaten
Titel
Refractory fibromyalgia
verfasst von
Luis F. Vidal
Osvaldo Messina
Tamara Rodríguez
Maritza Vidal
Carlos Pineda
Rasec Morales
Antonio Collado
Publikationsdatum
24.06.2021
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 9/2021
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05818-0

Weitere Artikel der Ausgabe 9/2021

Clinical Rheumatology 9/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.